Evidence-based personas put behaviour at the centre of customer intelligence

Tern plc

Personas are useful when they help a business understand how people think, decide and act. They are less useful when they simply create a polished version of what a customer might say. That distinction is becoming more important as artificial intelligence makes it easier to generate convincing customer profiles at speed.

Synthetic personas can appear highly realistic. They can answer questions, react to messages and simulate preferences. This makes them useful for quick testing, creative development and early exploration. The risk is that they may reflect what a model assumes a person would say rather than what real people are likely to do.

Evidence-based personas take a different approach. They are built from real-life data and behavioural signals, with synthetic data used to improve and optimise the model. This matters because commercial decisions need more than plausible language. They need insight into behaviour, timing, barriers, motivations and likely action.

Synthetic personas focus mainly on what people say. Evidence-based personas focus on what people do. That makes them more relevant when decisions carry greater risk, when audiences are complex, or when timing matters. In sectors such as healthcare and life sciences, where customer behaviour can be shaped by regulation, professional context and patient need, a stronger evidence base can improve the quality of decision-making.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Fundamental XR builds case for wider surgical simulation adoption

Fundamental XR is expanding the role of virtual simulation in surgical training as hospitals integrate the technology into structured education programmes.

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Search